FMS-related tyrosine kinase 3 (FLT3) mutations are detected in approximately 25–30% of acute myeloid leukemia (AML) patients, thus representing one of the most frequent mutations in AML [1]. This evidence concerns the gene FLT3 and acute myeloid leukemia.